Drug Topics e-News:
Having trouble viewing this email? View in a browser.
|
You are subscribed to %%list.name%% as %%emailaddr%%. Unsubscribe.
|
to Drug Topics e-News
|
|
|
|
 |
 |
| Newest: Diabetic peripheral neuropathy |
| For pharmacists, from Drug Topics: Continuing education for pharmacists and pharmacy technicians. Go to CE site here |
|
|
|
|
Survey
This month we would like to know...
Have the security arrangements for your pharmacy been increased since the June pharmacy robbery/murders in Long Island?
• Yes
• Not yet, but plans are in the works
• We do not plan to increase security
|
|
|
The concentration of the influenza drug oseltamivir phosphate (Tamiflu, Genentech) for oral suspension has been reduced from 12 mg/mL to 6 mg/mL to reduce the possibility of prescribing and dosing confusion that can lead to medication errors, FDA announced.
Read full article. |
 |
|
|
To confirm your e-newsletter subscription, click here.
To ensure future delivery of email newsletters from
Drug Topics, please take a moment to confirm your subscription by clicking here.
Thank you,
Drug Topics Staff
|
 |
A discussion generated by
Drug Topics’ readers, editorial staff, and advisory board
Robert Katz has been a practicing pharmacist for 40 years. |
What makes a good pharmacy? Read full article.
|
|
After the North Dakota legislature defeated a bill to overturn the state's pharmacy ownership law this year, a group is working to get the issue on the 2012 general election ballot. Read full article.
|
|
Potential Medicare budget cuts made through a new board are likely to significantly reduce healthcare access for beneficiaries, according to testimony presented to the U.S. House Energy and Commerce health subcommittee. Read full article.
|
|
After assessing new evidence, the U.S. Centers for Disease Control and Prevention released revised recommendations for postpartum contraceptive use, announced an article published in the July 8 issue of Morbidity and Mortality Weekly Report. Read full article.
|
|
Concerned about the increasing potential in gonorrhea patients for resistance to cephalosporin, the Centers for Disease Control and Prevention now recommends dual therapy for gonorrhea, with ceftriaxone 250 mg plus either azithromycin or doxycycline. Read full article.
|
|
In this section we showcase products and product news that ran up against space limitations or fell outside the parameters of recently featured categories in the print edition. Look for more OTC Product News in upcoming issues of the Drug Topics e-newsletter. Read full article.
 |
Meetings and Events
July 22-25, 2011 NPhA Annual Convention
Atlanta
Contact:
107 Kilmayne Drive, Suite C
Cary, NC 27511
Phone: 404-262-3344
Fax: 404-262-8689
August 3-6, 2011 AADE Annual meeting and exhibition
Las Vegas
Contact:
800-338-3633 ext. 4878.
meetings@aadenet.org
August 27-30, 2011 NACDS Pharmacy & Technology Conference
Boston
Contact:
P.O. Box 34814
Alexandria, VA 22334-0814
703-683-5678
October 6-7, 2011 NCPA Diabetes Accreditation
Standards-Practical Applications (DASPA)
Nashville, TN
Contact:
100 Daingerfield Road
Alexandria, VA 22314
800-544-7447
October 8-12 2011 NCPA Annual Convention
Nashville, TN
Contact:
100 Daingerfield Road
Alexandria, VA 22314
800-544-7447
November 29, 2011 NACDS Foundation 13th Annual Dinner
New York, NY
Contact:
Jennifer Sargeant, Manager, Foundation Programs and Education, NACDS
703-837-4224
|
|
|
|
| Contact Us |
Contact a Drug Topics editor Click Here
Contact a Drug Topics sales representative Click Here
Learn about direct mail, reprints and classifieds in Drug Topics Click Here |
You are subscribed to %%list.name%% as %%emailaddr%%. Click here to unsubscribe or edit your member profile.
To ensure delivery to your inbox, please add us to your address book. If you need help doing this, Click here.
Advanstar Communications provides certain customer contact data (such as customers' names, addresses, phone numbers and e-mail addresses) to third parties who wish to promote relevant products, services and other opportunities which may be of interest to you. If you do not want Advanstar Communications to make your contact information available to third parties for marketing purposes, simply call (toll free) 866-529-2922 at any time, or
fax us at 218-740-6417. Outside the U.S., please phone 218-740-6395. Contact us by mail at Advanstar Communications Inc., 131 West First St., Duluth, MN 55802-2065, USA.
|
|
